Eliaz Therapeutics Awarded $ 1.7 Million by NIH for XGAL3’s Apheresis Massive Animal Security Examine
SANTA ROSA, California, June 23, 2022 / PRNewswire / – Eliaz Therapeutics Inc (ETI), a therapeutic apheresis firm, was awarded its second NIH grant, an SBIR Section 2 grant for $ 1.7 million. ETI has developed a singular, patented medical system for eradicating Galectin-3 (Gal-3) from human blood. XGAL3® removes each certain and free Gal-3 … Read more